6 mercaptopurine

Summary

Summary: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.

Top Publications

  1. ncbi Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials
    Ramya Ramanujachar
    Department of Molecular Haematology, Institute of Child Health, London, United Kingdom
    Pediatr Blood Cancer 48:254-61. 2007
  2. ncbi Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice
    Natalia F Krynetskaia
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA
    Mol Pharmacol 64:456-65. 2003
  3. ncbi Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells
    Meyling H Cheok
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 332 N. Lauderdale St, Memphis, Tennessee 38105 USA
    Nat Genet 34:85-90. 2003
  4. ncbi Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, CDRC P, Portland, OR 97239 3098, USA
    J Clin Oncol 25:5800-7. 2007
  5. ncbi Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides
    John A Duley
    Chemical Pathology Department, Mater Health Services, Brisbane, Queensland, Australia
    Ther Drug Monit 27:647-54. 2005
  6. ncbi Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells
    T Dervieux
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
    Cancer Res 61:5810-6. 2001
  7. ncbi HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy
    Thierry Dervieux
    Department of. Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    Clin Chem 48:61-8. 2002
  8. ncbi Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists
    T M Wallace
    Department of Medicine, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Canada
    Can J Gastroenterol 15:21-8. 2001
  9. ncbi [Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients]
    Yi Xia
    Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, P.R.China
    Ai Zheng 23:1448-50. 2004
  10. ncbi Efficacy of conventional immunosuppressive drugs in IBD
    R Caprilli
    GI Unit, Department of Clinical Science, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy
    Dig Liver Dis 36:766-80. 2004

Research Grants

  1. MOLECULAR CORRELATES OF METHOTREXATE IN CHILDHOOD ALL
    Larry Matherly; Fiscal Year: 2007
  2. Function of the MRP Family
    GARY KRUH; Fiscal Year: 2006
  3. Ethnic Differences in Survival after Childhood ALL
    Smita Bhatia; Fiscal Year: 2009
  4. PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)
    William Evans; Fiscal Year: 2007
  5. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2004
  6. Function of the MRP Family
    GARY KRUH; Fiscal Year: 2006
  7. IMP Dehydrogenase and the Hydra of Cancer Chemotherapy
    GEORGE MARKHAM; Fiscal Year: 2007
  8. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 1980
  9. MRP4 IN DRUG SENSITIVITY AND PHYSIOLOGY
    John Schuetz; Fiscal Year: 2007
  10. IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE
    BRUCE SANDS; Fiscal Year: 2004

Detail Information

Publications187 found, 100 shown here

  1. ncbi Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials
    Ramya Ramanujachar
    Department of Molecular Haematology, Institute of Child Health, London, United Kingdom
    Pediatr Blood Cancer 48:254-61. 2007
    ..This analysis adds further emphasis to the treatment approach and the merits and limitations of treatment of adolescents on paediatric and adult trials...
  2. ncbi Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice
    Natalia F Krynetskaia
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA
    Mol Pharmacol 64:456-65. 2003
    ..Together, these findings establish that hematopoietic toxicity in vivo after treatment with mercaptopurine is attenuated but not abolished by MSH2 deficiency...
  3. ncbi Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells
    Meyling H Cheok
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, 332 N. Lauderdale St, Memphis, Tennessee 38105 USA
    Nat Genet 34:85-90. 2003
    ....
  4. ncbi Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, CDRC P, Portland, OR 97239 3098, USA
    J Clin Oncol 25:5800-7. 2007
    ..However, prognosis after relapse continues to be poor. We examined postrelapse outcomes of children initially treated on the Children's Cancer Group CCG-1952 study...
  5. ncbi Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides
    John A Duley
    Chemical Pathology Department, Mater Health Services, Brisbane, Queensland, Australia
    Ther Drug Monit 27:647-54. 2005
    ..Difficult questions remain to be answered, which may be assisted by technological advances. Prospective TGN studies, long overdue, are at last revealing clearer results...
  6. ncbi Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells
    T Dervieux
    Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
    Cancer Res 61:5810-6. 2001
    ....
  7. ncbi HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy
    Thierry Dervieux
    Department of. Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    Clin Chem 48:61-8. 2002
    ..5 pmol/5 x 10(6) cells. CONCLUSIONS: This method is suitable for measurement of thiopurine metabolite concentrations in lymphoblasts in children with acute lymphoblastic leukemia following a single dose of intravenous mercaptopurine...
  8. ncbi Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists
    T M Wallace
    Department of Medicine, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Canada
    Can J Gastroenterol 15:21-8. 2001
    ..The evidence in support of pancreatic and hepatic monitoring is weak. The risk of non-Hodgkin's lymphoma is likely low...
  9. ncbi [Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients]
    Yi Xia
    Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, P.R.China
    Ai Zheng 23:1448-50. 2004
    ..From the clinical data, a high serum level was not found associated with stage, gender, PS. score, IPI score, serum LDH and "B" symptoms et al...
  10. ncbi Efficacy of conventional immunosuppressive drugs in IBD
    R Caprilli
    GI Unit, Department of Clinical Science, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy
    Dig Liver Dis 36:766-80. 2004
    ..Various factors may account for this change of view. Aim of the present review was to summarise key information currently available regarding the use of immunosuppressive drugs in the treatment of inflammatory bowel disease...
  11. ncbi The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol
    Vladimir Mihal
    Department of Pediatrics, Faculty of Medicine, Palacky University and Faculty Hospital, Olomouc, Czech Republic
    Bull Cancer 91:E80-9. 2004
    ....
  12. ncbi The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment
    S A Coulthard
    University of Newcastle upon Tyne, Northern Institute for Cancer Research, Medical School, Newcastle upon Tyne, UK
    Nucleosides Nucleotides Nucleic Acids 23:1385-91. 2004
    ..An overview of the polymorphisms identified to date, their implication on the metabolism of the thiopurine drugs and therapeutic importance will be discussed...
  13. ncbi [Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD]
    W Reinisch
    Univ.-Klinik f. Innere Medizin IV, Abteilung Gastroenterologie und Hepatologie, AKH Wien, Austria
    Z Gastroenterol 42:1033-45; discussion 1046-7. 2004
    ..The risk of malignancy using immunosuppressive drugs such as AZA is low and furthermore, especially AZA and 6-MP can be used rather safely during pregnancy...
  14. ncbi [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases]
    Xiao Fei Sun
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong 510060, P R China
    Ai Zheng 23:1687-91. 2004
    ..BFM-90 regimen for lymphoblastic lymphoma is one of the most effective regimens. This study was designed to evaluate efficacy and toxicities of modified BFM-90 regimen on Chinese children and adolescents with lymphoblastic lymphoma...
  15. ncbi [Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group]
    Katarzyna Derwich
    Katedra i Klinika Onkologii, Hematologii i Transplantologii Pediatrycznej Akademii Medycznej w Poznaniu
    Przegl Lek 61:49-52. 2004
    ..77 (0.02) and 0.79 (0.02), respectively. Application of high dose of methotrexate is effective in prevention of relapses, especially meningeal and testicular involvement...
  16. ncbi Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
    Jeremy Sanderson
    Departments of Purine Research and Gastroenterology, Guy s and St Thomas Hospitals, London SE1 7EH, UK
    Ann Clin Biochem 41:294-302. 2004
    ..This article reviews literature on the role of TPMT measurement prior to treatment with thiopurines and provides some guidance to the use of TPMT as a guide to tailoring thiopurine therapy...
  17. ncbi General principles of medical therapy of inflammatory bowel disease
    Sonia Friedman
    Gastroenterology Division ASBII, Department of Medicine, Harvard Medical School, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Gastroenterol Clin North Am 33:191-208, viii. 2004
    ..Finally, it provides a summary of the current accepted medical therapies for ulcerative colitis adn Crohn's disease and recommendations for using these medications in clinical practice...
  18. ncbi Pharmacogenetics and inflammatory bowel disease: progress and prospects
    Gwo-Tzer Ho
    Department of Gastroenterology, Western General Hospital, Edinburgh EH, 4 2XU
    Inflamm Bowel Dis 10:148-58. 2004
  19. ncbi High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait
    Hubert Mottl
    Medical Oncology Department, Kuwait Cancer Control Centre, Shuwaikh, Kuwait
    Pediatr Hematol Oncol 20:103-10. 2003
    ..Six patients are in 1st CR and one died due to progression of disease. Despite the small group of patients, the results suggest that NHL BFM 95 protocol is highly effective and safe with regular supportive care...
  20. ncbi Benign intracranial hypertension in association with acute lymphoblastic leukemia
    J Sastry
    Department of Pediatric Oncology, Llandough Hospital, Cardiff, UK
    Pediatr Hematol Oncol 20:157-60. 2003
  21. ncbi [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects]
    M Schwab
    , Stuttgart
    Dtsch Med Wochenschr 128:378-85. 2003
  22. ncbi Inflammatory bowel disease: management issues during pregnancy
    Simone Ferrero
    Dipartimento di Ostetricia e Ginecologia, Universita degli Studi di Genova, Padiglione 1, Ospedale San Martino, Largo R Benzi 1, 16132, Genova, Italy
    Arch Gynecol Obstet 270:79-85. 2004
    ..Inflammatory bowel disease often affects women during their reproductive years, causing management concerns for obstetricians caring for these patients during pregnancy...
  23. ncbi Position statement: immunomodulator therapy for inflammatory Bowel disease
    Alexandra Lavy
    Department of Gastroenterology, Bnei Zion Medical Center and Technion Faculty of Medicine, Haifa, Israel
    Isr Med Assoc J 5:164-9. 2003
  24. ncbi [The assessment of plasma levels of insulin-like growth factor (IGF-I) and binding protein (IGFBP-3) during the maintenance therapy and after remissionof acute lymphoblastic leukemia (ALL)]
    Maryna Krawczuk-Rybak
    , , Poland
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 9:35-40. 2003
    ..CONCLUSIONS: 1. IGF-1 and IGFBP-3 values are dependent on puberty degree, body mass index and height. 2. IGF-1 SDS are lower and IGFBP-3 values higher, independent on gender, therapy protocol and CNS prophylaxis (12 Gy)...
  25. ncbi [The influence of age, gender and modifications of therapeutic protocols on physical development of children and adolescents after completion of therapy for acute lymphoblastic leukemia]
    Maryna Krawczuk-Rybak
    , , Poland
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 9:41-7. 2003
    ..ALL treatment contributes to the increase of body mass, which is kept until therapy completed, especially in the group of girls. 2. Growth rate including children with CNS prophylaxis does not submit significantly disturbances...
  26. ncbi Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia
    Thomas Efferth
    Virtual Campus Rhineland Palatinate, D 55126 Mainz, Germany
    Int J Oncol 23:509-17. 2003
    ..Homo- or heterozygosity did not correlate to survival of patients in the Kaplan-Meier analysis. In conclusion, we do not have reason to assume that the C3435T SNP contributes to drug resistance of ALL and prognosis of ALL patients...
  27. ncbi [Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic]
    J Stary
    II dĕtská klinika 2 LF UK a FNM, Praha
    Cas Lek Cesk 142:404-9. 2003
    ..The authors report the treatment outcome in children with ALL cured according to ALL-BFM 90 Study protocol in the Czech Republic during the first half of nineties...
  28. ncbi Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia
    Melchior Lauten
    Hannover Medical School, Pediatric Hematology and Oncology, 30625 Hannover, Germany
    Haematologica 88:1253-8. 2003
    ..The protein expression of the GR has been linked to in vivo and in vitro GC resistance in various diseases treated with GC. However, existing data are conflicting...
  29. ncbi [Results of the treatment of childhood acute lymphoblastic leukemia according to the Berlin-Moscow-91 protocol in 1991-2000]
    N V Miakova
    Research Institute of Pediatric Hematology and Oncology, Ministry of Health of the RF, Russian Children's Clinical Hospital, Moscow
    Vopr Onkol 48:340-6. 2002
    ..Toxic side-effects after L-asparaginase were reported in 27 (7.9%). It is concluded that good results in childhood ALL treatment can be achieved without resorting to high-dosage chemotherapy and radiation in most cases...
  30. ncbi Review article: monitoring of immunomodulators in inflammatory bowel disease
    F N Aberra
    Department of Medicine, Center for Inflammatory Bowel Disease, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, 3400 Spruce Street, 3rd Floor Ravdin Building, Philadelphia, PA 19104-4283, USA
    Aliment Pharmacol Ther 21:307-19. 2005
    ..This review provides the latest information for clinicians on efficacy, side-effects, dosing and monitoring of these medications for treatment of inflammatory bowel disease...
  31. ncbi [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease]
    Javier P Gisbert
    Servicio de Aparato Digestivo Hospital Universitario de La Princesa Universidad Autónoma Madrid España
    Gastroenterol Hepatol 29:568-83. 2006
    ....
  32. ncbi Childhood CD4+/CD56+ hematodermic neoplasm: case report and review of the literature
    Antonio Ruggiero
    Division of Paediatric Oncology, Department of Paediatric Sciences, Catholic University, Largo A Gemelli 8 00168 Rome, Italy
    Haematologica 91:ECR48. 2006
    ..Moreover, we try to analyse features and outcome of a few other paediatric CD4+/CD56+ hematodermic tumours as they are reported in the literature...
  33. ncbi [Reults of treatment with protocols BFM 90 and BFM 95]
    Meliha Sakić
    Pedijatrijska klinika, KCU Sarajevo
    Med Arh 60:369-72. 2006
    ..Children treated in accordance to the protocol BFM 90 there were 24 % of the children who died, and 12,6 % of the children who were treated in accordance to the protocol 95 died...
  34. ncbi Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine
    Karin Dilger
    Dr Falk Pharma GmbH, Freiburg, Germany
    Ther Drug Monit 29:1-5. 2007
    ..4. In a well-standardized clinical setting of inflammatory bowel disease, neither mesalazine nor azathioprine significantly affected TPMT activity during a whole year of treatment...
  35. ncbi [Auditory evoked potentials in patients after acute children's lymphoblastic leukemia treatment]
    Slawomir Kroczka
    Pracownia Neurofizjologii Kliniki Neurologii, Dzieciecej Uniwersytetu Jagiellońskiego
    Przegl Lek 63:1205-9. 2006
    ..ALL and its treatment as well, may cause disturbances of central transmission of acoustic stimuli...
  36. ncbi [Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma]
    Xiao Fei Sun
    Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, Cancer Center of Sun Yat Sen University, Guangzhou 510060, China
    Zhonghua Zhong Liu Za Zhi 29:58-61. 2007
    ..This study was designed to evaluate the efficacy and toxicity of modified BFM-90 regimen originated from Germany authors in the treatment of Chinese childhood and adolescent lymphoblastic lymphoma...
  37. ncbi Evaluation of renal function in Turkish children receiving BFM-95 therapy for acute lymphoblastic leukemia
    Zuhre Kaya
    Hematology Unit, Department of Pediatrics, Medical School of Gazi University, Ankara, Turkey
    Pediatr Hematol Oncol 24:257-67. 2007
    ..1 +/- 12.5 months after completion chemotherapy. These data show that consolidation therapy with HDMTX is frequently associated with acute renal toxicity in children with ALL but does not leave clinically significant late sequelae...
  38. ncbi [The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity]
    A I Karachunskiĭ
    Ter Arkh 79:19-26. 2007
    ..A comparative analysis of efficacy and toxicity of two chemotherapy regimens: standard German protocol ALL-BFM 90m and less intensive original test protocol ALL-MB 91 in a multicenter trial of acute lymphoblastic leukemia (ALL) in children...
  39. ncbi Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy
    Maurizio Arico
    Pediatric Hematology Oncology, Ospedale dei Bambini G Di Cristina, Palermo, Italy
    J Clin Oncol 26:283-9. 2008
    ..The prognostic value of DNA index was explored in this setting...
  40. ncbi [Benefits and risks of immunosuppression in chronic inflammatory bowel diseases]
    G Rogler
    , ,
    Dtsch Med Wochenschr 133:1917-21. 2008
  41. ncbi Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia
    Juan Manuel Sancho
    Clinical Hematology Department, Institut Català d Oncologia Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Eur J Haematol 78:102-10. 2007
    ..We present the results of treatment of Philadelphia chromosome-negative (Ph-) ALL patients over 55 yr treated in the PETHEMA ALL-96 trial...
  42. ncbi Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs
    Sharon J Gardiner
    Department of Clinical Pharmacology, Christchurch Hospital and Christchurch School of Medicine, Christchurch, New Zealand
    Br J Clin Pharmacol 62:453-6. 2006
    ..To determine infant exposure to 6-thioguanine and 6-methylmercaptopurine nucleotides (6-TGN and 6-MMPN, respectively) during maternal use of azathioprine in breastfeeding...
  43. ncbi Next steps on the thiopurine methyltransferase 6-thioguanine nucleotide pathway
    Richard B Colletti
    J Pediatr Gastroenterol Nutr 43:282-3. 2006
  44. ncbi T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia
    Elpis Mantadakis
    Department of Pediatric Hematology Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece
    Pediatr Blood Cancer 48:354-7. 2007
    ..This report suggests that a subset of CD7+ T-cell leukemias without mature T-cell antigens (CD4-, CD8-) are minimally differentiated and can relapse as AML...
  45. ncbi Membranous glomerulopathy in children given allogeneic hematopoietic stem cell transplantation
    Silverio Perrotta
    Department of Pediatrics, Second University of Naples, Italy
    Haematologica 90:ECR31. 2005
    ..Therefore, we strongly suggest regular urine analysis during the follow-up of children undergoing HSCT in order to diagnose MG early...
  46. ncbi The thiopurines: an update
    Sally Coulthard
    Leukaemia Research Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
    Invest New Drugs 23:523-32. 2005
    ..A possible relationship between TPMT and secondary malignancies is also reviewed...
  47. ncbi p16 inactivation associated with aggressive clinical course and fatal outcome in TEL/AML1-positive acute lymphoblastic leukemia
    Stefanos I Papadhimitriou
    Hematology Laboratory, G Gennimatas Athens Regional General Hospital, Athens, Greece
    J Pediatr Hematol Oncol 27:675-7. 2005
    ....
  48. ncbi Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies
    Andrea Biondi
    Centro Ricerche Leucemie Infantili M Tettamanti, Clinica Pediatrica Università Milano Bicocca, Monza, Italy
    Haematologica 91:534-7. 2006
    ..The corresponding figures for patients treated in the ALL-91 high-risk protocol (reduced induction and nine blocks) were one of seven patients treated with chemotherapy only and none of two who were transplanted...
  49. ncbi 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine
    Scott Hande
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Inflamm Bowel Dis 12:251-7. 2006
    ..We tested the theory that coadministration of 5-ASA agents with AZA/6-MP results in higher 6-TGn levels in a large cohort of children and adults with CD or ulcerative colitis (UC)...
  50. ncbi Pharmacogenetics in inflammatory bowel disease
    Marie Pierik
    Department of Gastro enterology, University of Hospital Gasthuisberg, Leuven, Belgium
    World J Gastroenterol 12:3657-67. 2006
    ..An effort should be made to collect genomic DNA from all patients enrolled in clinical drug trials after appropriate informed consent for pharmacogenetic studies...
  51. ncbi Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia
    Daniel Ka Leung Cheuk
    Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China
    Pediatr Blood Cancer 50:636-9. 2008
    ..Early recognition and complete resection is important for achieving a good outcome. Careful monitoring for recurrence or a third malignancy is needed...
  52. ncbi Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis
    Michael A Heneghan
    Department of Gastroenterology, Duke University Medical Center, Durham, NC 27710, USA
    J Hepatol 45:584-91. 2006
    ..Our aims were to evaluate the role of TPMT genotyping and phenotyping and to examine 6-TG and 6-MMP metabolite levels in patients with AIH...
  53. ncbi Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia
    Takuro Nishikawa
    Department of Pediatrics, Kagoshima City Hospital, Kagoshima University Graduate School of Medical, Kagoshima, Japan
    J Pediatr Hematol Oncol 30:519-21. 2008
    ..VCR has previously been considered to be relatively safe in CMT type 2, however, some patients with CMT type 2 might show severe neurologic toxicities, as seen in patients with CMT type 1...
  54. ncbi Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate
    Elpis Mantadakis
    Pediatric Hematology/Oncology Clinic, PEPAGNI University Hospital of Iraklio, Crete, Greece
    J Pediatr Hematol Oncol 24:636-42. 2002
    ..CONCLUSIONS: In the context of effective prolonged divided-dose oral methotrexate-based therapy in the treatment of BCP-ALL, methotrexate accumulation and polyglutamation no longer seem to have prognostic significance...
  55. ncbi Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy
    J Grenzebach
    Department of Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany
    Ann Hematol 80:B73-6. 2001
    ..Providing tumor regression within 5 weeks is sufficient, tumor remnants after induction have weak prognostic impact...
  56. ncbi Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate
    Birgitta Pettersson
    Department of Clinical Pharmacology, University Hospital, , Sweden
    Ther Drug Monit 24:351-8. 2002
    ..The results show that the role of thiopurine metabolism for drug effects is complex...
  57. ncbi Increased factor VIII activity and dural sinus thrombosis
    Tiraje Celkan
    Med Pediatr Oncol 39:71-2. 2002
  58. ncbi [Twenty years of treating childhood acute lymphoblastic leukemia]
    A Perez Martinez
    Servicio de Hematología Oncología y Trasplante Hematopoyético Hospital Niño Jesús Madrid España
    An Pediatr (Barc) 65:198-204. 2006
    ..Conventional prognostic factors for relapse in patients with acute lymphoblastic leukemia (ALL) are the main basis of risk-stratified treatments...
  59. ncbi Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia
    Charles Linker
    Bone Marrow Transplant Program, Medical Center, University of California San Francisco, 400 Parnassus Avenue, Rm A502, San Francisco, CA 94143 0324, USA
    J Clin Oncol 20:2464-71. 2002
    ..To assess the efficacy and toxicity of a new treatment program of intensified and shortened cyclical chemotherapy (protocol 8707) in adults with acute lymphoblastic leukemia (ALL)...
  60. ncbi Variant translocations of 11q23 in infant acute lymphoblastic leukemia (ALL): do outcomes differ from t(4;11)?
    Zsuzsanna Jakab
    Department of Pediatrics, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
    Med Pediatr Oncol 39:63-5. 2002
  61. ncbi Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia
    Ottavio Ziino
    Pediatric Hematology Oncology, Ospedale dei Bambini G. Di Cristina, Palermo, Italy
    Med Pediatr Oncol 39:32-4. 2002
    ..CONCLUSIONS: SH is a rare complication associated with administration of the purine analogues, mercaptopurine and thioguanine to children with reduced fat storage and young age...
  62. ncbi Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors
    F Locatelli
    Oncoematologia Pediatrica, IRCCS Policlinico San Matteo, , Italy
    Leukemia 16:2228-37. 2002
    ..EFS of unrelated donor HSCT in children with ALL in second CR has improved in the last few years, mainly due to a decreased TRM. This information is of value for counseling of patients with relapsed ALL...
  63. ncbi Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
    P W Lowry
    Division of Gastroenterology, Division of Clinical Pharmacology, Department of Pharmacology, and Section of Biostatistics, Mayo Clinic, Rochester, MN, USA
    Gut 49:656-64. 2001
    ....
  64. ncbi High performance liquid chromatography analysis of hypoxanthine metabolism in mouse oocyte-cumulus cell complexes: effects of purine metabolic perturbants
    S M Downs
    Biology Department, Marquette University, Milwaukee, Wisconsin 53233
    Biol Reprod 50:1403-12. 1994
    ..In addition, whereas metabolism favors conversion of IMP to adenyl nucleotides, synthesis of adenyl nucleotides by this route during the culture period is apparently not required for hypoxanthine-maintained meiotic arrest in vitro...
  65. ncbi IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases
    S G Meuwissen
    International Organization for the Study of Inflammatory Bowel Disease, Department of Gastroenterology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands
    Eur J Gastroenterol Hepatol 12:13-8. 2000
    ....
  66. ncbi [Hospital spread of scabies from an immunocompromised patient with Norwegian scabies]
    H Iwasaki
    First Department of Internal Medicine, Fukui Medical School, Japan
    Kansenshogaku Zasshi 65:1194-9. 1991
    ..The persons with scabies were treated with crotamiton liniment. The first scabies patient died of cardiac failure 1 month after falling into a coma.(ABSTRACT TRUNCATED AT 250 WORDS)..
  67. ncbi Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement
    R Caprilli
    Promoter Centre, GI Unit, Department of Clinical Science, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy
    Dig Liver Dis 37:407-17. 2005
    ..Despite the explosion of biological therapies, the old immunosuppressants continue to play a pivotal role in the management of inflammatory bowel diseases...
  68. ncbi [Pellagra]
    Palokinam T Pitche
    Service de Dermatologie, CHU Tokoin, Faculté de médecine et de pharmacie de Lomé, BP 81056 Lomé, Togo
    Sante 15:205-8. 2005
    ..The prevention is based in the nutritional education (food sources of niacin: eggs, bran, peanuts, meat, poultry, fish, red meat, legumes and seeds), and the eviction of alcohol...
  69. ncbi Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease
    J Belaiche
    Service de Gastroenterologie, CHU Sart Tilman, Liege, Belgium
    Scand J Gastroenterol 36:71-6. 2001
    ..The aims of the study were to evaluate the RBC 6TGN concentrations in adult patients with CD under long-term AZA/6-MP therapy and to correlate it with response to treatment and haematological parameters...
  70. ncbi Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications
    Hiroko Kunitake
    Department of Surgery, Massachusetts General Hospital, 15 Parkman Street, ACC 460, Boston, MA 02114, USA
    J Gastrointest Surg 12:1730-6; discussion 1736-7. 2008
    ..We examined a large patient cohort to clarify whether a relationship exists between IFX and postoperative complications...
  71. ncbi The fidelity of replication of the three-base-pair set adenine/thymine, hypoxanthine/cytosine and 6-thiopurine/5-methyl-2-pyrimidinone with T7 DNA polymerase
    Harry P Rappaport
    Biology Department, Temple University, Philadelphia, PA 19122, USA
    Biochem J 381:709-17. 2004
    ..The level of fidelity of replication of the three base pairs with T7 DNA polymerase suggests that they are adequate for a three-base-pair alphabet for DNA replication...
  72. ncbi Methotrexate compared with mercaptopurine for early induced abortion
    A R Davis
    Department of Obstetrics and Gynecology, Columbia University, New York, New York 10032, USA
    Obstet Gynecol 93:904-9. 1999
    ..To compare the antimetabolites methotrexate and 6-mercaptopurine as single-agent medical abortifacients using clinical and immunohistochemical analyses...
  73. ncbi Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA
    R Honchel
    Department of Pharmacology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905
    Mol Pharmacol 43:878-87. 1993
    ..Cloning of cDNA for this important drug-metabolizing enzyme may make it possible to define the molecular basis of the TPMT genetic polymorphism in humans...
  74. ncbi Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites
    Galal H Elgemeie
    Chemistry Department, Faculty of Science, Helwan University, Ain Helwan, Cairo, Egypt
    Curr Pharm Des 9:2627-42. 2003
    ..This review will focus on mercaptopurine analogs and their nucleosides as antimetabolite agents...
  75. ncbi Hypersensitivity reactions to chemotherapeutic drugs
    Gillian M Shepherd
    Weill Medical College of Cornell University, New York, NY, USA
    Clin Rev Allergy Immunol 24:253-62. 2003
    ..Reaction rates may vary with different forms of the drugs, e.g. pegylated. Occasionally excipients such as Cremaphor EL may induce hypersensitivity reactions...
  76. ncbi On the effect of thalidomide on Mycobacterium avium subspecies paratuberculosis in culture
    Robert J Greenstein
    VAMC Bronx NY 112, 130 West Kingsbridge Rd, Bronx, NY 10468, USA
    Int J Infect Dis 13:e254-63. 2009
    ..We herein test the hypothesis that thalidomide may inhibit MAP growth...
  77. ncbi Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease
    T Stevens
    Department of Gastroenterology and Hepatology, Center for Inflammatory Bowel Disease, Cleveland Clinic Foundation, OH 44195, USA
    Aliment Pharmacol Ther 20:601-6. 2004
    ..Recent studies have suggested that mercaptopurine metabolism is influenced by drug formulation (mercaptopurine vs. azathioprine) and concomitant use of 5-aminosalicylic acid medications...
  78. ncbi Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children
    M P Sullivan
    Division of Pediatrics, University of Texas M D Anderson Hospital and Tumor Institute, Houston 77030
    Cancer Chemother Pharmacol 21:78-84. 1988
    ..Further trials using DON in combination with thiopurines or other agents appear indicated...
  79. ncbi Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1
    Christopher J Endres
    Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
    Biochem J 380:131-7. 2004
    ....
  80. ncbi Antitumor activity of sugar-modified cytosine nucleosides
    Akira Matsuda
    Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita ku, Sapporo 060 0812, Japan
    Cancer Sci 95:105-11. 2004
    ....
  81. ncbi Factors affecting recurrence after surgery for Crohn's disease
    Takayuki Yamamoto
    Inflammatory Bowel Disease Center and Department of Surgery, Yokkaichi Social Insurance Hospital, 10 8 Hazuyamacho, Yokkaichi, Mie 510 0016, Japan
    World J Gastroenterol 11:3971-9. 2005
    ..A wider anastomotic technique after resection may reduce the post-operative recurrence rate, though this should be investigated with prospective randomized controlled trials...
  82. ncbi Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease
    C Cuffari
    Division of Gastroenterology, Department of Paediatrics, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Gut 48:642-6. 2001
    ..Measurement of erythrocyte 6-TG metabolite levels has been proposed as a useful clinical tool for assessing treatment efficacy in patients with inflammatory bowel disease (IBD)...
  83. ncbi Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio
    Sharon J Gardiner
    Department of Medicine, University of Otago, Christchurch, New Zealand
    J Gastroenterol Hepatol 26:49-54. 2011
    ..The aim of the present study was to investigate the effect of allopurinol on concentrations of 6-MMPN and 6-TGN in individuals with a high ratio of these metabolites (>20), which is indicative of a poor thiopurine response...
  84. ncbi Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis
    Eugene F Yen
    Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, California 94143 0538, USA
    Am J Gastroenterol 103:3094-105. 2008
    ..The relative benefits and costs of maintenance 5-ASA therapy are uncertain. Our aims were to evaluate this strategy's potential cost-effectiveness...
  85. ncbi 6-Mercaptopurine attenuates adhesive molecules in experimental vasospasm
    Chih Zen Chang
    Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China
    Acta Neurochir (Wien) 152:861-7. 2010
    ..The present study was to examine whether levels of adhesion molecules were altered after treatment with 6-mp in this animal model...
  86. ncbi Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease
    Jean Paul Achkar
    Center for Inflammatory Bowel Disease, Departments of Gastroenterology and Biostatistics, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Inflamm Bowel Dis 10:339-45. 2004
    ..The purpose of this study was to assess the relation between clinical response, 6-mercaptopurine metabolite levels, relative leukopenia, and drug dose...
  87. ncbi Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase)
    Anthony M Marinaki
    Purine Research Laboratory, Department of Chemical Pathology and Department of Gastroenterology, Guy s and St Thomas Hospital, London, UK
    Pharmacogenetics 14:181-7. 2004
    ..5, 95% CI 1.4-21.3, P = 0.0206). Polymorphism in the ITPA gene predicts AZA intolerance. Alternative immunosuppressive drugs, particularly 6-thioguanine, should be considered for AZA-intolerant patients with ITPase deficiency...
  88. ncbi Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamole
    Christopher J Endres
    Department of Pharmaceutics, Box 357610, University of Washington, Seattle, WA 98195, USA
    Mol Pharmacol 67:837-44. 2005
    ..In contrast, Ser160 and Met89 of hENT1, respectively, play a dominant role in conferring sensitivity to dipyridamole and adenosine/guanosine affinity...
  89. ncbi Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting
    Houssam E Mardini
    University of Pittsburgh Medical Center Shadyside, Pennsylvania 15232, USA
    J Clin Gastroenterol 36:390-5. 2003
    ..A 6-MMP level of >5,700 pmol/8 x 108 RBCs has been reported to be associated with an increased frequency of abnormal results of liver function tests (LFTs)...
  90. ncbi [Treatment of chronic inflammatory bowel diseases]
    Marc Lemann
    Service de Gastroenterologie, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris
    Bull Acad Natl Med 191:1125-41; discussion 1141. 2007
    ..The choice of maintenance therapy depends on the nature of the disease (HRC or CD) and its progressive nature. Surgery is reserved for patients with complicated and drug-resistant forms...
  91. ncbi Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule
    P A Zubizarreta
    Hematology Oncology Department, Hospital de Pediatria SAMIC Professor Dr J P Garrahan, Buenos Aires, Argentina
    Pediatr Hematol Oncol 17:155-62. 2000
    ..Moreover, survival results did not improve with this method of ATRA usage. Longer periods of ATRA administration during APL therapy are strongly recommended...
  92. ncbi Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease
    Stephen A Geller
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 28:1204-11. 2004
    ..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease...
  93. ncbi [Second neoplasm in a 13-year-old boy complicated by Crohn's disease. Case report]
    Joanna Nurzyńska-Flak
    Klinika Hematologii i Onkologii Dzieciecej, Dzieciecy Szpital Kliniczny, Chodzki 2, 20 093 Lublin, Poland
    Med Wieku Rozwoj 8:839-45. 2004
    ..CONCLUSION: The differential diagnosis of complications accompanying neoplasms should consider the inflammatory bowel diseases; their atypical course may be masked by the treatment of the underlying disease...
  94. ncbi [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia]
    Grazyna Lisowska
    Katedra i Oddział Kliniczny Laryngologii w Zabrzu Sl AM w Katowicach
    Otolaryngol Pol 60:415-20. 2006
    ....
  95. ncbi Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease
    Yukari Masunaga
    Student, Graduate School of Pharmaceutical Sciences, Department of Pharmacy, Hatsudai Rehabilitation Hospital, Tokyo
    Ann Pharmacother 41:21-8. 2007
    ..There is a concern as to whether long-term administration of immunosuppressants in patients with inflammatory bowel disease (IBD) would increase the risk of malignancy...
  96. ncbi The use of nucleotide analogs to evaluate the mechanism of the heterotropic response of Escherichia coli aspartate transcarbamoylase
    J B Sakash
    Department of Chemistry, Merkert Chemistry Center, Boston College, Massachusetts 02467, USA
    Protein Sci 9:53-63. 2000
    ....
  97. ncbi Autologous hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: still not out of fashion
    Michael Doubek
    Department of Internal Medicine Hematooncology, University Hospital in Brno and Masaryk University, Brno, Czech Republic
    Ann Hematol 88:881-7. 2009
    ....
  98. ncbi [Refractory anemia with excess myeloblast in transformation induced remission by combined oral administration of cytarabine ocfosfate and 6-mercaptopurine]
    S Fukumi
    Dept of Internal Medicine I, Daisan Hospital, Jikei University School of Medicine
    Gan To Kagaku Ryoho 22:945-8. 1995
    ..Observation suggested that oral SPAC in combination with 6-mercaptopurine had a good antileukemic effect on the myelodysplastic syndrome. However, the duration response was short, and further improvement of the therapy is needed...
  99. ncbi Renal cellular transport, metabolism, and cytotoxicity of S-(6-purinyl)glutathione, a prodrug of 6-mercaptopurine, and analogues
    L H Lash
    Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Biochem Pharmacol 54:1341-9. 1997
    ..Administration of 6-PG may be an effective means of treating renal tumors or suppressing renal transplant rejection...
  100. ncbi Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines
    L V Ramilo-Torno
    Department of Pediatrics, School of Medicine, University of Southern California, Los Angeles
    Cancer Chemother Pharmacol 35:191-9. 1995
    ..The combination also exerts collateral sensitivity in the ara-C-resistant cell lines. 6-MP pretreatment may play a role in enhancing ara-C activation, thus producing drug synergism in sensitive and resistant leukemia cell lines...
  101. ncbi Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity
    J Romagnuolo
    Department of Gastroenterology, University of Alberta, Edmonton
    Can J Gastroenterol 12:479-83. 1998
    ....

Research Grants70

  1. MOLECULAR CORRELATES OF METHOTREXATE IN CHILDHOOD ALL
    Larry Matherly; Fiscal Year: 2007
    ..abstract_text> ..
  2. Function of the MRP Family
    GARY KRUH; Fiscal Year: 2006
    ..These experiments should provide a more complete picture of the potential for this complex family of unusual pumps to impact cancer treatment. ..
  3. Ethnic Differences in Survival after Childhood ALL
    Smita Bhatia; Fiscal Year: 2009
    ..abstract_text> ..
  4. PHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)
    William Evans; Fiscal Year: 2007
    ..These findings will continue to provide important new insights into the genomic determinants of treatment failure and point to novel targets for developing strategies to overcome drug resistance in childhood ALL. ..
  5. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2004
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  6. Function of the MRP Family
    GARY KRUH; Fiscal Year: 2006
    ..These experiments should provide a more complete picture of the potential for this complex family of unusual pumps to impact cancer treatment. ..
  7. IMP Dehydrogenase and the Hydra of Cancer Chemotherapy
    GEORGE MARKHAM; Fiscal Year: 2007
    ..These results will reveal the inner working of an essential enzyme and whether there is promise for enhancing clinical efficacy through combinations of known drugs or the discovery of novel subdomain ligands. ..
  8. INHERITED VARIATIONS IN DRUG METABOLIZING ENZYMES
    Richard Weinshilboum; Fiscal Year: 1980
    ....
  9. MRP4 IN DRUG SENSITIVITY AND PHYSIOLOGY
    John Schuetz; Fiscal Year: 2007
    ..Cumulatively, these studies will increase our knowledge of this increasingly important ABC transporter and provide insight into how Mrp4 plays a role in hematopoietic cells and the liver ..
  10. IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE
    BRUCE SANDS; Fiscal Year: 2004
    ..The principal investigator seeks to become an independent clinical investigator by completing the didactic and scientific portions of this proposal. ..